Antibiotic Therapy for Infected Burns
For hospitalized patients with infected burns, empirical IV vancomycin (15-20 mg/kg every 8-12 hours) combined with piperacillin-tazobactam (4.5g every 6-8 hours) or a carbapenem should be initiated immediately, with therapy duration of 7-14 days based on clinical response. 1
Initial Empirical Therapy
The IDSA guidelines explicitly classify infected burns as complicated skin and soft tissue infections (cSSTI), requiring broad-spectrum coverage for both MRSA and gram-negative organisms including Pseudomonas aeruginosa 1.
First-line IV options include:
- Vancomycin 15-20 mg/kg every 8-12 hours (monitor trough levels, target 15-20 mcg/mL) PLUS
- Piperacillin-tazobactam 4.5g every 6-8 hours 1, 2
Alternative combinations:
- Vancomycin + cefepime 2g every 8-12 hours 3
- Vancomycin + carbapenem (meropenem 1g every 8 hours or imipenem 1g every 6-8 hours) 3, 4
- Linezolid 600mg IV/PO twice daily (can replace vancomycin) 1
- Daptomycin 4 mg/kg IV daily (alternative to vancomycin) 1
The combination approach is critical because burn wounds harbor polymicrobial infections with evolving resistance patterns—initially gram-positive organisms predominate, but gram-negative pathogens (particularly Pseudomonas and Acinetobacter) emerge during hospitalization 2, 5, 6.
Dosing Considerations Specific to Burns
Burn patients require higher and more frequent antibiotic doses due to altered pharmacokinetics: increased volume of distribution, enhanced hepatic metabolism, and augmented renal clearance 7. For piperacillin-tazobactam specifically, studies demonstrate that burn patients need 4.5g every 6 hours (not the standard every 8 hours) to maintain adequate drug levels 8, 2.
Duration of Therapy
7-14 days is recommended, individualized to clinical response 1. The Surviving Sepsis Campaign guidelines support 7-10 days for most serious infections, with longer courses only for slow clinical response or undrainable foci 3.
De-escalation Strategy
Narrow therapy within 3-5 days once culture results and sensitivities are available 3. Obtain cultures from burn wounds before initiating antibiotics—blood cultures and tissue biopsies (not swabs) are essential 1. Tissue biopsy with quantitative culture (>10^5 organisms/gram) is the gold standard for confirming invasive infection versus colonization 5, 6.
Critical Pitfall: Antibiotic Prophylaxis
Do NOT use sustained systemic antibiotic prophylaxis in burn patients without documented infection 3, 9. The Surviving Sepsis Campaign explicitly recommends against prophylactic antibiotics in severe inflammatory states of noninfectious origin, including burn injury, as this promotes antimicrobial resistance without proven benefit 3. The 2020 European burn guidelines similarly advise against routine prophylaxis 9.
Pediatric Dosing
For children with infected burns:
- Vancomycin 15 mg/kg every 6 hours IV 1
- Clindamycin 10-13 mg/kg every 6-8 hours IV (if clindamycin resistance <10% locally) 1
- Linezolid 10 mg/kg every 8 hours for children <12 years (600mg twice daily for ≥12 years) 1
- Avoid tetracyclines in children <8 years 1
Adjunctive Measures
Surgical debridement remains the cornerstone—antibiotics alone are insufficient without source control 1, 4. For colistin-resistant gram-negative organisms, colistin (polymyxin E) has re-emerged as effective salvage therapy, though nephrotoxicity monitoring is essential 2.
Monitoring Parameters
- Blood cultures at 2-4 days to document clearance if bacteremic 10
- Vancomycin trough levels (target 15-20 mcg/mL for serious infections)
- Renal function (burn patients have altered clearance requiring dose adjustments) 7
- Clinical response by 72 hours—failure to improve warrants imaging for undrained collections and culture review 1